Results of cardiac marker proficiency test for subgroups during the 2020-2nd EQA program
| Test substance | Instrument | No. of labs | CCA-20-04 (pooled human serum) | CCA-20-05 (pooled human serum) | CCA-20-06 (commercial control material) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean±SD | CV (%) | Mean±SD | CV (%) | Mean±SD | CV (%) | |||||
| TnI | All | 362 | 0.179±0.138 | 77.1 | 0.227±0.174 | 76.8 | 5.220±2.696 | 51.6 |
||
| ADVIA Centaur XPT | 12 | 0.362±0.029 | 8.1 | 0.468±0.038 | 8.0 | 17.602±0.671 | 3.8 | |||
| ARCHITECT i1000 | 22 | 0.360±0.026 | 7.1 | 0.452±0.033 | 7.3 | 7.359±0.549 | 7.5 | |||
| ARCHITECT i2000 | 56 | 0.365±0.024 | 6.7 | 0.452±0.03 | 6.7 | 7.142±0.435 | 6.1 | |||
| UniCel DxI800 | 34 | 0.022±0.002 | 10.0 | 0.026±0.002 | 9.2 | 5.253±0.196 | 3.7 | |||
| Pathfast | 33 | 0.051±0.007 | 14.4 | 0.068±0.009 | 13.9 | 4.839±0.507 | 10.5 | |||
| AFIAS-6 | 17 | 0.175±0.015 | 8.3 | 0.220±0.018 | 8.2 | 9.704±0.835 | 8.6 | |||
| AQT90 FLEX | 52 | 0.022±0.002 | 8.2 | 0.026±0.003 | 10.8 | 1.153±0.057 | 5.0 | |||
| cobas4000 e411 | 41 | 0.164±0.032 | 19.5 | 0.207±0.032 | 15.5 | 3.945±0.332 | 8.4 | |||
| cobas6000 e601 | 17 | 0.159±0.021 | 13.2 | 0.200±0.024 | 12.2 | 3.596±0.175 | 4.9 | |||
| TnT | All | 114 | 0.156±0.006 | 3.7 | 0.197±0.007 | 3.6 | 1.674±0.531 | 31.7 |
||
| cobas e801 | 29 | 0.157±0.005 | 3.0 | 0.199±0.005 | 2.5 | 2.116±0.162 | 7.7 | |||
| cobas4000 e411 | 51 | 0.156±0.006 | 4.0 | 0.199±0.009 | 4.4 | 1.124±0.129 | 11.5 | |||
| cobas6000 e601 | 15 | 0.154±0.005 | 3.3 | 0.196±0.007 | 3.3 | 2.05±0.209 | 10.2 | |||
| cobas8000 e602 | 19 | 0.153±0.006 | 3.7 | 0.194±0.005 | 2.6 | 2.028±0.2 | 9.9 | |||
| BNP | All | 85 | NA | NA | NA | NA | 1,382.0±167.3 | 12.1 | ||
| ARCHITECT i2000 | 23 | NA | NA | NA | NA | 1,414.4±143.6 | 10.2 | |||
| UniCel DxI800 | 15 | NA | NA | NA | NA | 1,265.5±41.5 | 3.3 | |||
| Triage Meter-pro | 15 | NA | NA | NA | NA | 615.4±109.5 | 17.8 | |||
| NT-proBNP | All | 296 | 6,295.9±360.3 | 5.7 | 8,020.3±412.7 | 5.2 | 4,604.6±2,399.0 | 52.1 |
||
| cobas e801 | 38 | 6,042.1±162.9 | 2.7 | 7,795.5±199.2 | 2.6 | 3,287.5±122.7 | 3.7 | |||
| cobas4000 e411 | 68 | 6,282.7±228.1 | 3.6 | 8,134.6±330.7 | 4.1 | 2,705.3±161.5 | 6.0 | |||
| cobas6000 e601 | 29 | 6,242.5±221.6 | 3.6 | 7,922.2±225.4 | 2.8 | 3,415.1±236.6 | 6.9 | |||
| cobas8000 e602 | 26 | 6,158.7±183.8 | 3.0 | 7,958.3±238.3 | 3.0 | 3,425.1±240.4 | 7.0 | |||
| Pathfast | 28 | 5,820.1±657.0 | 11.3 | 7,588.7±712.5 | 9.4 | 10,402.2±808 | 7.8 | |||
| AQT90 FLEX | 45 | 6,462.3±250.2 | 3.9 | 8,115.8±365.4 | 4.5 | 6,767.2±291.2 | 4.3 | |||
| AFIAS-6 | 10 | 6,623.4±540.9 | 8.2 | 8,660.5±678.1 | 7.8 | 20,055.5±1,957.2 | 9.8 | |||
| ARCHITECT i2000 | 16 | 7,335.1±336.9 | 4.6 | 9,370.6±464.8 | 5.0 | 4,120.6±232.2 | 5.6 | |||
The instruments used in 10 or more institutions during the 2020-2nd EQA program are presented in the table. The level of BNP, which in ethylenediaminetetraacetic acid-plasma is a suitable specimen recommended by the test manufacturer, was measured in commercial material only. The instruments used were from the following companies: Siemens (Tarrytown, NY, USA), Abbott (Abbott Park, IL, USA), Beckman Coulter (Brea, CA, USA), Polymedco (Cortlandt Manor, NY, USA), Boditech Med Inc. (Chuncheon, Korea), Radiometer (Brønshøj, Denmark), Roche (Mannheim, Germany), and Quidel Corp. (San Diego, CA, USA).
Abbreviations: EQA, external quality assessment; SD, standard deviation; CV, coefficient of variation; TnI, troponin I; TnT, troponin T; BNP, brain natriuretic peptide; NA, not available; NT-proBNP, N-terminal pro-brain natriuretic peptide.
*CCA-20-06, the commercial control material with high concentration of cardiac marker, showed higher CV% compared to other materials.